OMDABullishOmada Health presents ObesityWeek 2026 real-world outcomesnews
Medium materiality5/10
Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026
Nov 16, 2026, 9:44 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
These real-world outcomes may improve Omada’s value proposition to employers, payers and clinicians by demonstrating higher patient engagement and GLP-1 persistence, which could support demand for its virtual care programs and thus revenue; this is conditional on payer adoption and commercial translation.
AI summary
What happened, with direct paths to the underlying reporting
Omada reported ObesityWeek 2026 analyses showing its AI Meal Map raised meal-tracking and was associated with slightly greater 16-week weight loss, and its GLP-1 Care Track had 71% 12-month medication persistence with 18.4% weight loss for those persistent.
Omada’s AI Meal Map increased the share of members who tracked at least three meals in their first month to 41.1% versus 36.0% for control.
Members who tracked at least three meals in their first month and used Meal Map lost 3.47% body weight at week 16 versus 3.02% for the control group.
In Omada’s GLP-1 Care Track analysis, 71% of members stayed on GLP-1 medication at 52 weeks and those who stayed on medication the full year lost an average of 18.4% body weight.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Omada Health will prescribe GLP-1 drugs starting in 2026. TrumpRx announces significant discounts for GLP-1 medications. Omada aims to ease complexities for primary care providers…
Omada Health to prescribe GLP-1s, enhancing its weight management program. Membership exceeds 100,000, indicating strong growth potential. Market for GLP-1s could reach $100 billi…
Omada reported Q2 revenue of $61 million, exceeding estimates. Net loss decreased to $5.31 million, showing improved financial health. The company expects 2023 revenue to reach $2…
Omada Health raised $150 million in its IPO. The stock debuted on Nasdaq under the symbol 'OMDA'. OMDA's valuation exceeds $1 billion post-IPO. This reflects increasing investor i…